Introduction Executive Summary Nonalcoholic steatohepatitis (NASH): Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Nonalcoholic steatohepatitis (NASH) – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Nonalcoholic steatohepatitis (NASH) companies’ collaborations, Licensing, Acquisition -Deal Value Trends Nonalcoholic steatohepatitis (NASH) Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Preregistration) ● Comparative Analysis Oltipraz: Pharmaking ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis TERN-101: Terns Pharmaceuticals ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) ● Comparative Analysis EDP 297: Enanta Pharmaceuticals ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products ● Comparative Analysis Drug Name: Company Name ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Nonalcoholic steatohepatitis (NASH) Key Companies Nonalcoholic steatohepatitis (NASH) Key Products Nonalcoholic steatohepatitis (NASH)- Unmet Needs Nonalcoholic steatohepatitis (NASH)- Market Drivers and Barriers Nonalcoholic steatohepatitis (NASH)- Future Perspectives and Conclusion Nonalcoholic steatohepatitis (NASH) Analyst Views Nonalcoholic steatohepatitis (NASH) Key Companies Appendix

Table 1 Total Products for Nonalcoholic steatohepatitis (NASH) Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Madrigal Pharmaceuticals • Pharmaking • Galmed Pharmaceuticals • Cirius Therapeutics • Enanta Pharmaceuticals • ENYO pharma • Terns Pharmaceuticals • Oramed pharmaceuticals • Lipocin • AstraZeneca • Guangdong Zhongsheng Pharmaceutical • Alnylam Pharmaceuticals • Intercept Pharmaceuticals • Galectin Therapeutics Inc. • Bristol-Myers Squibb • Poxel SA • Akero Therapeutics, Inc • Boehringer Ingelheim • Metacrine, Inc. • Inventiva Pharma • Viking Therapeutics, Inc. • Pfizer • Hanmi Pharmaceutical Company Limited • Celgene • Sagimet Biosciences Inc.